Statements (63)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Searle_Pharmaceuticals
|
gptkbp:activities |
dopamine receptor antagonist
|
gptkbp:approves |
gptkb:1990
gptkb:FDA |
gptkbp:associated_with |
improved quality of life
reduction in hospitalizations improved social functioning lower risk of suicide |
gptkbp:brand |
gptkb:Clozaril
Faza Clo |
gptkbp:caused_by |
gptkb:hospital
gptkb:Company metabolic syndrome hyperlipidemia pulmonary embolism hyperglycemia extrapyramidal symptoms QT prolongation neuroleptic malignant syndrome myocarditis |
gptkbp:clinical_trial |
Phase III
50% to 60% |
gptkbp:contraindication |
history of agranulocytosis
|
gptkbp:developed_by |
gptkb:Sandoz
|
gptkbp:discontinued |
in patients with severe CNS depression
|
gptkbp:disease_resistance |
treatment-resistant schizophrenia
|
gptkbp:dosage_form |
300 to 900 mg/day
|
gptkbp:healthcare |
gptkb:1990
|
https://www.w3.org/2000/01/rdf-schema#label |
Clozapine
|
gptkbp:ingredients |
C18 H19 Cl N4
|
gptkbp:interacts_with |
gptkb:beer
benzodiazepines CY P2 D6 inhibitors CY P3 A4 inhibitors |
gptkbp:is_atype_of |
N05 A H02
|
gptkbp:is_available_in |
multiple countries
|
gptkbp:is_available_on |
gptkb:tablet
oral suspension |
gptkbp:is_effective_against |
cognitive symptoms of schizophrenia
negative symptoms of schizophrenia |
gptkbp:is_monitored_by |
white blood cell count
|
gptkbp:is_used_for |
treatment of schizophrenia
|
gptkbp:lifespan |
12 hours
|
gptkbp:manager |
oral
|
gptkbp:metabolism |
CY P1 A2
|
gptkbp:requires |
patient registry for monitoring
|
gptkbp:research_focus |
genetic factors
neuroinflammation pharmacogenomics neurotransmitter systems |
gptkbp:side_effect |
dizziness
seizures constipation weight gain sedation tachycardia agranulocytosis hypersalivation |
gptkbp:suitable_for |
elderly patients with dementia-related psychosis
|
gptkbp:treatment |
not first-line treatment
|
gptkbp:uses |
requires regular blood tests
|